Testing effectiveness (Phase 2)Ended earlyNCT02315625
What this trial is testing
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Neoplasms+2 more
National Cancer Institute (NCI) 16